Message from our CEO
Our Culture & Values
Clinical Operations & Monitoring
Statistical Science & Operations
Medical Writing & Translation
PV & Medical Monitoring
R&G PharmaStudies Co., Ltd. have recently merged with Suzhou HQ Bioscience Co., Ltd. Suzhou HQ Bioscience is now a subsidiary of R&G. Dr. Dafang ZHONG signed the Merger Agreement with R&G on behalf of Suzhou HQ Bioscience.
Dr. Gang CHEN has officially joined R&G PharmaStudies Co., Ltd., and has taken up the role of Chief Scientific Officer and Senior Vice President.
On August 22, 2008, R&G was established. After 8 years of hard work and struggle, on July 23, 2016, R&G submitted a formal IPO application to the China Securities Regulatory Commission. And from that point on, we have entered a new chapter in our story.
The 26thTranscatheter Cardiovascular Therapeutics(TCT) is held on September 13th to 17th in Washington D.C, U.S.A. For over 25 years, TCT has been the center of cutting-edge technology communication, experience sharing and education among the world’s intervention physicians. And TCT is currently the world’s most influential meeting specialized in interventional cardiovascular medicine.
The European Medicines Agency (EMA) has agreed in principle to publish clinical-trials reports on any drug that receives marketing approval in the European Union - and to do so proactively, without the need for formal freedom-of-information request.
The revised Regulations for the Supervision and Administration of Medical Devices was adopted at the 39th executive meeting of the State Council on February 12, 2014, and was put into force on June 1, 2014. On May 23, 2014, China Food and Drug Administration (CFDA) issued an announcement on the implementation of the Regulations for the Supervision and Administration of Medical Devices.
CDE drafted 8 technical guidance which has issued by CFDA on May 13, 2014, including “The guidance for drug safety pharmacology study”, “The guidance for single dose toxicity study”, “The guidance for repeated dose toxicity study”, “The guidance for non clinical pharmacokinetics study” and so on.
The 'quality' of the class of 2013 has never been in doubt, however. Each of the 10 largest growth drivers – based on consensus sales in 2018 – is expected to become blockbuster products within five years of approval. By FirstWord's estimations, using consensus data sourced from Bloomberg, these 10 products are expected to generate combined global sales of $34 billion by 2018.
Sovaldi brings US drug pricing to the fore, But also redefines the blockbuster launch, Immune-oncology continues to feed industry expectation, Big Pharma winners and losers, M&A remains in vogue, Diabetes market continues to fuel strong performances
R&G Shanghai Office has moved to the new address since the prior one can no longer fulfill its task due to R&G’s fast growth. The new site, after thorough screening and fine decoration, is located at 500 Guangdong Road, World Trade Tower, Suite 1602, Huangpu District.
© 2017 R&G PharmaStudies Co., Ltd. All Rights Reserved